AMP-activated protein kinase pathway and bone metabolism

Journal of Endocrinology

Volumn 212, Issue 3, 2012, Pages 277-290

  Jeyabalan, J ^a   Shah, M ^a   Viollet, B ^b   Chenu, C ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; A 79662; ADIPONECTIN; ANTIDIABETIC AGENT; BERBERINE; BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; FAT; GALLIC ACID; GHRELIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PIOGLITAZONE; PROPRANOLOL; PYRIDONE DERIVATIVE; QUERCETIN; ROSIGLITAZONE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UNCLASSIFIED DRUG;

APPETITE; BONE CELL; BONE METABOLISM; CELL ACTIVITY; CELL ENERGY; DELETION MUTANT; ENZYME STRUCTURE; HOMEOSTASIS; HORMONE ACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAMMAL; MEDIATOR RELEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ADIPOCYTES; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BONE AND BONES; ENERGY METABOLISM; ENZYME ACTIVATION; GENE DELETION; HUMANS; HYPOGLYCEMIC AGENTS; MICE; OSTEOGENESIS; OSTEOPOROSIS;

EID: 84857826929     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0306     Document Type: Review

References (177)

1. Ackert-Bicknell CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA & Rosen CJ 2009 Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology 150 1330-1340. (doi:10.1210/en.2008-0936)
2. Ahdjoudj S, Fromigue O & Marie PJ 2004 Plasticity and regulation of human bone marrow stromal osteoprogenitor cells: potential implication in the treatment of age-related bone loss. Histology and Histopathology 19 151-157.
3. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC & Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146 1226-1235. (doi:10. 1210/en.2004-0735)
4. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D & Small CJ 2004 AMP-activated protein kinase plays a role in the control of food intake. Journal of Biological Chemistry 279 12005-12008. (doi:10.1074/jbc.C300557200)
5. Arad M, Seidman CE & Seidman JG 2007 AMP-activated protein kinase in the heart: role during health and disease. Circulation Research 100 474-488. (doi:10.1161/01.RES.0000258446.23525.37)
6. Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E et al. 2007 Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. Journal of Endocrinological Investigation 30 RC26-RC30.
7. Berberoglu Z, Yazici AC & Demirag NG 2010 Effects of rosiglitazone on bone mineral density and remodelling parameters in postmenopausal 3diabetic women: a 2-year follow-up study. Clinical Endocrinology 73 305-312. (doi:10.1111/j.1365-2265.2010.03784.x)
8. Bolster DR, Crozier SJ, Kimball SR & Jefferson LS 2002 AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. Journal of Biological Chemistry 277 23977-23980. (doi:10.1074/jbc. C200171200)
9. Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA & Cobitz AR 2011 A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes, Obesity & Metabolism (In press). (doi:10.1111/j.1463-1326.2011.01461.x)
10. Burns KA & Vanden Heuvel JP 2007 Modulation of PPAR activity via phosphorylation. Biochimica et Biophysica Acta 1771 952-960. (doi:10.1016/j.bbalip.2007.04.018)
11. Canto C & Auwerx J 2010 AMP-activated protein kinase and its downstream transcriptional pathways. Cellular and Molecular Life Sciences 67 3407-3423. (doi:10.1007/s00018-010-0454-z)
12. Cao X & Chen D 2005 The BMP signaling and in vivo bone formation. Gene 357 1-8. (doi:10.1016/j.gene.2005.06.017)
13. Carling D 2004 The AMP-activated protein kinase cascade - a unifying system for energy control. Trends in Biochemical Sciences 29 18-24. (doi:10. 1016/j.tibs.2003.11.005)
14. Carling D, Fryer LG, Woods A, Daniel T, Jarvie SL & Whitrow H 2003 Bypassing the glucose/fatty acid cycle: AMP-activated protein kinase. Biochemical Society Transactions 31 1157-1160. (doi:10.1042/BST0311157)
15. Carling D, Sanders MJ & Woods A 2008 The regulation of AMP-activated protein kinase by upstream kinases. International Journal of Obesity 32 (Suppl 4) S55-S59. (doi:10.1038/ijo.2008.124)
16. Cho SW, Yang JY, Her SJ, Choi HJ, Jung JY, Sun HJ, An JH, Cho HY, Kim SW, Park KS et al. 2011 Osteoblast-targeted overexpression of PPARgamma inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice. Journal of Bone and Mineral Research 26 1939-1952. (doi:10.1002/jbmr.366)
17. Cornish J, Callon KE & Reid IR 1996 Insulin increases histomorphometric indices of bone formation In vivo. Calcified Tissue International 59 492-495. (doi:10.1007/s002239900163)
18. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC et al. 2002 Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. Journal of Endocrinology 175 405-415. (doi:10.1677/joe.0.1750405)
19. Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A & Schurman L 2006 Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. European Journal of Pharmacology 536 38-46. (doi:10.1016/j.ejphar. 2006.02.030)
20. Corton JM, Gillespie JG, Hawley SA & Hardie DG 1995 5-Aminoimidazole- 4-carboxamide ribonucleoside. A specific method for activating AMPactivated protein kinase in intact cells? European Journal of Biochemistry 229 558-565. (doi:10.1111/j.1432-1033.1995.tb20498.x)
21. DavalM, Diot-Dupuy F, Bazin R, Hainault I, Viollet B, Vaulont S, Hajduch E, Ferre P & Foufelle F 2005 Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. Journal of Biological Chemistry 280 25250-25257. (doi:10.1074/jbc.M414222200)
22. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P et al. 2005 Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporosis International 16 1330-1338. (doi:10.1007/s00198-005-1863-y)
23. Delany AM, Dong Y & Canalis E 1994 Mechanisms of glucocorticoid action in bone cells. Journal of Cellular Biochemistry 56 295-302. (doi:10.1002/jcb. 240560304)
24. Ducy P 2000 Cbfa1: a molecular switch in osteoblast biology. Developmental Dynamics 219 461-471. (doi:10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>O3.0.CO;2-C)
25. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM & Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 197-207. (doi:10.1016/S0092-8674(00)81558-5)
26. Dunford JE 2010 Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Current Pharmaceutical Design 16 2961-2969. (doi:10.2174/138161210793563617)
27. Dytfeld J, Ignaszak-Szczepaniak M, Gowin E, Michalak M & Horst-Sikorska W 2011 Influence of lean and fat mass on bone mineral density (BMD) in postmenopausal women with osteoporosis. Archives of Gerontology and Geriatrics 53 e237-e242. (doi:10.1016/j.archger.2011.01.002)
28. Dzamko NL & Steinberg GR 2009 AMPK-dependent, hormonal regulation of whole-body energy metabolism. Acta Physiologica 196 115-127. (doi:10. 1111/j.1748-1716.2009.01969.x)
29. Edwards BJ, Bunta AD, Simonelli C, BolanderM& Fitzpatrick LA 2007 Prior fractures are common in patients with subsequent hip fractures. Clinical Orthopaedics and Related Research 461 226-230. (doi:10.1097/BLO. 0b013e3180534269)
30. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M et al. 2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434 514-520. (doi:10.1038/nature03398)
31. Ewart MA & Kennedy S 2011 AMPK and vasculoprotection. Pharmacology and Therapeutics 131 242-253. (doi:10.1016/j.pharmthera.2010.11.002)
32. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P & Karsenty G 2010 Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142 296-308. (doi:10. 1016/j.cell.2010.06.003)
33. Fogarty S & Hardie DG 2010 Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochimica et Biophysica Acta 1804 581-591. (doi:10.1016/j.bbapap.2009.09.012)
34. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F & Viollet B 2010 Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Journal of Clinical Investigation 120 2355-2369. (doi:10.1172/JCI40671)
35. Fryer LG, Parbu-Patel A & Carling D 2002 The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. Journal of Biological Chemistry 277 25226-25232. (doi:10.1074/jbc.M202489200)
36. Fulzele K, RiddleRC, DiGirolamo DJ, Cao X,Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Bruning JC et al. 2010 Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142 309-319. (doi:10.1016/j.cell.2010.06.002)
37. Gao S, Kinzig KP, Aja S, Scott KA, KeungW, Kelly S, Strynadka K, Chohnan S, Smith WW, Tamashiro KL et al. 2007 Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. PNAS 104 17358-17363. (doi:10.1073/pnas.0708385104)
38. Gao Y, Li Y, Xue J, Jia Y & Hu J 2010 Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. European Journal of Pharmacology 635 231-236. (doi:10.1016/j.ejphar.2010.02.051)
39. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM & Morris DC 1996 Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Molecular Pharmacology 50 1087-1094.
40. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP & Brunet A 2007 The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. Journal of Biological Chemistry 282 30107-30119. (doi:10.1074/jbc.M705325200)
41. Grey A 2008 Skeletal consequences of thiazolidinedione therapy. Osteoporosis International 19 129-137. (doi:10.1007/s00198-007-0477-y)
42. Grey A 2009 Thiazolidinedione-induced skeletal fragility - mechanisms and implications. Diabetes, Obesity and Metabolism 11 275-284. (doi:10.1111/j. 1463-1326.2008.00931.x)
43. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J & Reid IR 2007 The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism 92 1305-1310. (doi:10.1210/jc.2006-2646)
44. Hardie DG 2003 Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144 5179-5183. (doi:10. 1210/en.2003-0982)
45. Hardie DG 2004 AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Medicine and Science in Sports and Exercise 36 28-34. (doi:10.1249/01.MSS.0000106171.38299.64)
46. Hardie DG 2007 AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nature Reviews. Molecular Cell Biology 8 774-785. (doi:10. 1038/nrm2249)
47. Hardie DG 2008 AMPK: a key regulator of energy balance in the single cell and the whole organism. International Journal of Obesity 32 (Suppl 4) S7-12. (doi:10.1038/ijo.2008.116)
48. Hardie DG 2011 Sensing of energy and nutrients by AMP-activated protein kinase. American Journal of Clinical Nutrition 93 891S-896S. (doi:10.3945/ajcn.110.001925)
49. Hardie DG & Pan DA 2002 Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochemical Society Transactions 30 1064-1070. (doi:10.1042/BST0301064)
50. Hardie DG & Sakamoto K 2006 AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology 21 48-60. (doi:10.1152/physiol.00044.2005)
51. Hardie DG, Carling D & Carlson M 1998 The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annual Review of Biochemistry 67 821-855. (doi:10.1146/annurev.biochem.67.1.821)
52. Hardie DG, Hawley SA & Scott JW 2006 AMP-activated protein kinase - development of the energy sensor concept. Journal of Physiology 574 7-15. (doi:10.1113/jphysiol.2006.108944)
53. Harvey N, Dennison E & Cooper C 2010 Osteoporosis: impact on health and economics. Nature Reviews. Rheumatology 6 99-105. (doi:10.1038/nrrheum.2009.260)
54. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG & Hardie DG 2005 Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metabolism 2 9-19. (doi:10.1016/j.cmet.2005.05.009)
55. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM et al. 2010 Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metabolism 11 554-565. (doi:10.1016/j.cmet.2010. 04.001)
56. Holmes BF, Kurth-Kraczek EJ & Winder WW 1999 Chronic activation of 50-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. Journal of Applied Physiology 87 1990-1995.
57. Horiuchi N & Maeda T 2006 Statins and bone metabolism. Oral Disease 12 85-101. (doi:10.1111/j.1601-0825.2005.01172.x)
58. Hou CH, Tan TW& TangCH 2008 AMP-activated protein kinase is involved in COX-2 expression in response to ultrasound in cultured osteoblasts. Cellular Signalling 20 978-988. (doi:10.1016/j.cellsig.2008.01.013)
59. Hsu YH, Venners SA, Terwedow HA, Feng Y, Niu T, Li Z, Laird N, Brain JD, Cummings SR, Bouxsein ML et al. 2006 Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. American Journal of Clinical Nutrition 83 146-154.
60. Huypens P, Moens K, Heimberg H, Ling Z, Pipeleers D & Van de CasteeleM 2005 Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sciences 77 1273-1282. (doi:10.1016/j.lfs.2005.03.008)
61. Jager S, Handschin C, St-Pierre J & Spiegelman BM 2007 AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. PNAS 104 12017-12022. (doi:10.1073/pnas. 0705070104)
62. Jang WG, Kim EJ, Bae IH, Lee KN, Kim YD, Kim DK, Kim SH, Lee CH, Franceschi RT, Choi HS et al. 2011 Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 48 885-893. (doi:10.1016/j.bone.2010.12.003)
63. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ & Thompson CB 2005 AMP-activated protein kinase induces a p53- dependent metabolic checkpoint. Molecular Cell 18 283-293. (doi:10.1016/j.molcel.2005.03.027)
64. Jorgensen SB, Viollet B, Andreelli F, Frosig C, Birk JB, Schjerling P, Vaulont S, Richter EA &Wojtaszewski JF 2004 Knockout of the alpha2 but not alpha1 50-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4- carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. Journal of Biological Chemistry 279 1070-1079. (doi:10.1074/jbc.M306205200)
65. Kahn BB, Alquier T, Carling D & Hardie DG 2005 AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 1 15-25. (doi:10.1016/j.cmet.2004.12.003)
66. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP et al. 2008 Rosiglitazoneassociated fractures in type 2 diabetes: an analysis from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31 845-851. (doi:10.2337/dc07-2270)
67. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M & Sugimoto T 2007 Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biology 8 51. (doi:10.1186/1471-2121-8-51)
68. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M & Sugimoto T 2008 Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochemical and Biophysical Research Communications 375 414-419. (doi:10.1016/j.bbrc.2008.08.034)
69. Kanazawa I, Yamaguchi T, Yano S, Hayashi K, Yamauchi M & Sugimoto T 2009a Inhibition of the mevalonate pathway rescues the dexamethasoneinduced suppression of the mineralization in osteoblasts via enhancing bone morphogenetic protein-2 signal. Hormone and Metabolic Research 41 612-616. (doi:10.1055/s-0029-1220684)
70. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M & Sugimoto T 2009b Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. American Journal of Physiology. Endocrinology and Metabolism 296 E139-E146. (doi:10.1152/ajpendo.90677.2008)
71. Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD & Macdougald OA 2007 Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry 282 14515-14524. (doi:10.1074/jbc.M700030200)
72. Kang EH, Lee YJ, Kim TK, Chang CB, Chung JH, Shin K, Lee EY, Lee EB & Song YW 2010 Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Research & Therapy 12 R231. (doi:10. 1186/ar3218)
73. Kasai T, Bandow K, Suzuki H, Chiba N, Kakimoto K, Ohnishi T, Kawamoto S, Nagaoka E & Matsuguchi T 2009 Osteoblast differentiation is functionally associated with decreased AMP kinase activity. Journal of Cellular Physiology 221 740-749. (doi:10.1002/jcp.21917)
74. Kazgan N, Williams T, Forsberg LJ & Brenman JE 2010 Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase. Molecular Biology of the Cell 21 3433-3442. (doi:10.1091/mbc. E10-04-0347)
75. Kim JM, Jeong D, Kang HK, Jung SY, Kang SS & Min BM 2007 Osteoclast precursors display dynamic metabolic shifts toward accelerated glucose metabolism at an early stage of RANKL-stimulated osteoclast differentiation. Cellular Physiology and Biochemistry 20 935-946. (doi:10.1159/000110454)
76. Kim JE, Ahn MW, Baek SH, Lee IK, Kim YW, Kim JY, Dan JM & Park SY 2008 AMPK activator AICAR, inhibits palmitate-induced apoptosis in osteoblast. Bone 43 394-404. (doi:10.1016/j.bone.2008.03.021)
77. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB et al. 2005 Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. Journal of Biological Chemistry 280 25196-25201. (doi:10.1074/jbc.C500175200)
78. Kola B, Boscaro M, Rutter GA, Grossman AB & Korbonits M 2006 Expanding role of AMPK in endocrinology. Trends in Endocrinology and Metabolism 17 205-215. (doi:10.1016/j.tem.2006.05.006)
79. Komarova SV, Ataullakhanov FI & Globus RK 2000 Bioenergetics and mitochondrial transmembrane potential during differentiation of cultured osteoblasts. American Journal of Physiology. Cell Physiology 279 C1220-C1229.
80. Korbonits M, Goldstone AP, GueorguievM& Grossman AB 2004 Ghrelin - a hormone with multiple functions. Frontiers in Neuroendocrinology 25 27-68. (doi:10.1016/j.yfrne.2004.03.002)
81. Lage R, Dieguez C, Vidal-Puig A & Lopez M 2008 AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends in Molecular Medicine 14 539-549. (doi:10.1016/j.molmed.2008.09.007)
82. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ & Lecka-Czernik B 2007 Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148 2669-2680. (doi:10.1210/en. 2006-1587)
83. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB & Tomas E 2006 Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. American Journal of Physiology. Endocrinology and Metabolism 291 E175-E181. (doi:10.1152/ajpendo. 00453.2005)
84. Lecka-Czernik B 2010 Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Current Osteoporosis Reports 8 178-184. (doi:10.1007/s11914-010-0027-y)
85. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC & Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. Journal of Cellular Biochemistry 74 357-371. (doi:10.1002/(SICI)1097-4644(19990901)74:3 !357::AID-JCB5O3.0.CO;2-7)
86. Lee WH & Kim SG 2010 AMPK-dependent metabolic regulation by PPAR agonists. PPAR Research 2010. (doi:10.1155/2010/549101)
87. Lee Y, Naseem RH, Duplomb L, Park BH, Garry DJ, Richardson JA, Schaffer JE & Unger RH 2004 Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. PNAS 101 13624-13629. (doi:10. 1073/pnas.0405499101)
88. Lee K, Li B, Xi X, Suh Y & Martin RJ 2005 Role of neuronal energy status in the regulation of adenosine 50-monophosphate-activated protein kinase, orexigenic neuropeptides expression, and feeding behavior. Endocrinology 146 3-10. (doi:10.1210/en.2004-0968)
89. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY et al. 2007 Endocrine regulation of energy metabolism by the skeleton. Cell 130 456-469. (doi:10.1016/j.cell.2007. 05.047)
90. Lee YS, Kim YS, Lee SY, Kim GH, Kim BJ, Lee SH, Lee KU, Kim GS, Kim SW & Koh JM 2010 AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 47 926-937. (doi:10.1016/j.bone. 2010.08.001)
91. Leff T 2003 AMP-activated protein kinase regulates gene expression by direct phosphorylation of nuclear proteins. Biochemical Society Transactions 31 224-227. (doi:10.1042/BST0310224)
92. Levine YC, Li GK & Michel T 2007 Agonist-modulated regulation of AMPactivated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK/Rac1/Akt/endothelial nitric-oxide synthase pathway. Journal of Biological Chemistry 282 20351-20364. (doi:10.1074/jbc. M702182200)
93. Li M, Pan LC, Simmons HA, Li Y, Healy DR, Robinson BS, Ke HZ & Brown TA 2006 Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 39 796-806. (doi:10.1016/j.bone. 2006.04.008)
94. Lim CT, Kola B & Korbonits M 2010 AMPK as a mediator of hormonal signalling. Journal of Molecular Endocrinology 44 87-97. (doi:10.1677/JME- 09-0063)
95. Lopez JM 2008 Is ZMP the toxic metabolite in Lesch-Nyhan disease? Medical Hypotheses 71 657-663. (doi:10.1016/j.mehy.2008.06.033)
96. Lopez M, Lelliott CJ & Vidal-Puig A 2007 Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. Bioessays 29 248-261. (doi:10.1002/bies.20539)
97. Lopez M, Lage R, Saha AK, Perez-Tilve D, Vazquez MJ, Varela L, Sangiao-Alvarellos S, Tovar S, Raghay K, Rodriguez-Cuenca S et al. 2008 Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metabolism 7 389-399. (doi:10.1016/j.cmet.2008.03.006)
98. Maccarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, Netti C & Cocchi D 2005 Ghrelin regulates proliferation and differentiation of osteoblastic cells. Journal of Endocrinology 184 249-256. (doi:10.1677/joe.1. 05837)
99. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N et al. 2001 PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 2094-2099. (doi:10.2337/diabetes.50. 9.2094)
100. Mai Q, Zhang Z, Xu S, Lu M, Zhou R, Zhao L, Jia C,Wen Z, Jin D & Bai X 2011 Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. Journal of Cellular Biochemistry 112 2902-2909. (doi:10.1002/jcb.23206)
101. Mantovani J & Roy R 2011 Re-evaluating the general(ized) roles of AMPK in cellular metabolism. FEBS Letters 585 967-972. (doi:10.1016/j.febslet. 2010.12.015)
102. Mayer A, Denanglaire S, Viollet B, Leo O & Andris F 2008 AMP-activated protein kinase regulates lymphocyte responses to metabolic stress but is largely dispensable for immune cell development and function. European Journal of Immunology 38 948-956. (doi:10.1002/eji.200738045)
103. McBride A & Hardie DG 2009 AMP-activated protein kinase - a sensor of glycogen as well as AMP and ATP? Acta Physiologica 196 99-113. (doi:10. 1111/j.1748-1716.2009.01975.x)
104. McGee SL & Hargreaves M 2008 AMPK and transcriptional regulation. Frontiers in Bioscience 13 3022-3033. (doi:10.2741/2907)
105. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D & Kahn BB 2002 Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 339-343. (doi:10.1038/415339a)
106. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B,Mu J, Foufelle F, Ferre P, Birnbaum MJ et al. 2004 AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428 569-574. (doi:10.1038/nature02440)
107. Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnol V & Sedlinsky C 2010 Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. Journal of Bone and Mineral Research 25 211-221. (doi:10.1359/jbmr.090732)
108. Mooney MH, Fogarty S, Stevenson C, Gallagher AM, Palit P, Hawley SA, Hardie DG, Coxon GD, Waigh RD, Tate RJ et al. 2008 Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice. British Journal of Pharmacology 153 1669-1677. (doi:10.1038/bjp. 2008.37)
109. Moreno D, Knecht E, Viollet B & Sanz P 2008 A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Letters 582 2650-2654. (doi:10.1016/j.febslet.2008.06.044)
110. Motoshima H, Goldstein BJ, Igata M & Araki E 2006 AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. Journal of Physiology 574 63-71. (doi:10.1113/jphysiol.2006.108324)
111. Mukherjee A & Rotwein P 2009 Akt promotes BMP2-mediated osteoblast differentiation and bone development. Journal of Cell Science 122 716-726. (doi:10.1242/jcs.042770)
112. Oakhill JS, Scott JW & Kemp BE 2009 Structure and function of AMPactivated protein kinase. Acta Physiologica 196 3-14. (doi:10.1111/j.1748- 1716.2009.01977.x)
113. Oliaro-Bosso S, Calcio Gaudino E, Mantegna S, Giraudo E, Meda C, Viola F & Cravotto G 2009 Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol. Lipids 44 907-916. (doi:10.1007/s11745-009-3338-y)
114. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H & Shimomura I 2005 Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochemical and Biophysical Research Communications 331 520-526. (doi:10.1016/j.bbrc.2005.03.210)
115. Pang T, Zhang ZS, Gu M, Qiu BY, Yu LF, Cao PR, Shao W, Su MB, Li JY, Nan FJ et al. 2008 Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. Journal of Biological Chemistry 283 16051-16060. (doi:10.1074/jbc.M710114200)
116. de Paula FJ, Horowitz MC & Rosen CJ 2010 Novel insights into the relationship between diabetes and osteoporosis. Diabetes/Metabolism Research and Reviews 26 622-630. (doi:10.1002/dmrr.1135)
117. Pei L & Tontonoz P 2004 Fat's loss is bone's gain. Journal of Clinical Investigation 113 805-806.
118. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG et al. 2003 Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes and Development 17 1352-1365. (doi:10.1101/gad.1089403)
119. PremaorMO, Ensrud K, Lui L, Parker RA, Cauley J, Hillier TA, Cummings S & Compston JE 2011 Risk factors for nonvertebral fracture in obese older women. Journal of Clinical Endocrinology 96 2414-2421. (doi:10.1210/jc. 2011-0076)
120. Qi J, Gong J, Zhao T, Zhao J, Lam P, Ye J, Li JZ,Wu J, Zhou HM& Li P 2008 Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue. EMBO Journal 27 1537-1548. (doi:10.1038/emboj.2008.92)
121. Quinn JM, Tam S, Sims NA, Saleh H, McGregor NE, Poulton IJ, Scott JW, Gillespie MT, Kemp BE & van Denderen BJ 2010 Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB Journal 24 275-285. (doi:10.1096/fj.09-137158)
122. Reid IR 2008 Relationships between fat and bone. Osteoporosis International 19 595-606. (doi:10.1007/s00198-007-0492-z)
123. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, Lim TM & Cundy TF 1992 Determinants of total body and regional bone mineral density in normal postmenopausal women - a key role for fat mass. Journal of Clinical Endocrinology and Metabolism 75 45-51. (doi:10.1210/jc.75.1.45)
124. Reihill JA, Ewart MA, Hardie DG & Salt IP 2007 AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. Biochemical and Biophysical Research Communications 354 1084-1088. (doi:10.1016/j.bbrc.2007.01.110)
125. Rogers MJ, Crockett JC, Coxon FP & Monkkonen J 2010 Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49 34-41. (doi:10.1016/j.bone.2010.11.008)
126. Rosen CJ & Bouxsein ML 2006 Mechanisms of disease: is osteoporosis the obesity of bone? Nature Clinical Practice. Rheumatology 2 35-43. (doi:10. 1038/ncprheum0070)
127. Rossoni LV, Wareing M, Wenceslau C, Al-Abri M, Cobb C & Austin CE 2011 Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. Clinical Science 121 449-458. (doi:10.1042/CS20110259)
128. Russell RG,Watts NB, Ebetino FH & Rogers MJ 2008 Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 19 733-759. (doi:10.1007/s00198-007-0540-8)
129. Rutter GA, Da Silva Xavier G & Leclerc I 2003 Roles of 50-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochemical Journal 375 1-16. (doi:10.1042/BJ20030048)
130. Rzonca SO, Suva LJ, Gaddy D, Montague DC & Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145 401-406. (doi:10.1210/en.2003-0746)
131. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA & Carling D 2007 Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochemical Journal 403 139-148. (doi:10.1042/BJ20061520)
132. Scott JW, van Denderen BJ, Jorgensen SB, Honeyman JE, Steinberg GR, Oakhill JS, Iseli TJ, Koay A, Gooley PR, Stapleton D et al. 2008 Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chemistry & Biology 15 1220-1230. (doi:10.1016/j.chembiol.2008.10.005)
133. Scott JW, Oakhill JS & van Denderen BJ 2009 AMPK/SNF1 structure: a menage a trois of energy-sensing. Frontiers in Bioscience 14 596-610. (doi:10. 2741/3266)
134. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, Saxon L, Korbonits M & Chenu C 2010 AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone 47 309-319. (doi:10.1016/j.bone.2010.04.596)
135. Shah M, Viollet B, KorbonitsM& Chenu C 2011 Deletion of Amp-activated protein kinase (AMPK)-alpha 1 catalytic subunit in mice impairs the in vivo response of bones to hormonal challenges. Bone 48 S96-S96. (doi:10.1016/j.bone.2011.03.139)
136. Shen Z, Liang X, Rogers CQ, Rideout D & You M 2010 Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. American Journal of Physiology. Gastrointestinal and Liver Physiology 298 G364-G374. (doi:10.1152/ajpgi. 00456.2009)
137. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N & Walsh K 2005 Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX- 2-dependent mechanisms. Nature Medicine 11 1096-1103. (doi:10.1038/nm1295)
138. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D & Karaplis AC 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. Journal of Endocrinology 183 203-216. (doi:10.1677/joe.1. 05723)
139. Sottile V, Seuwen K & Kneissel M 2004 Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcified Tissue International 75 329-337. (doi:10.1007/s00223-004-0224-8)
140. Steinberg GR & Jorgensen SB 2007 The AMP-activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini Reviews in Medicinal Chemistry 7 519-526. (doi:10.2174/1389557077806 19662)
141. Steinberg GR & Kemp BE 2009 AMPK in health and disease. Physiological Reviews 89 1025-1078. (doi:10.1152/physrev.00011.2008)
142. Steinberg GR, Watt MJ & Febbraio MA 2009 Cytokine regulation of AMPK signalling. Frontiers in Bioscience 14 1902-1916. (doi:10.2741/3350)
143. Sugatani T & Hruska KA 2005 Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. Journal of Biological Chemistry 280 3583-3589. (doi:10.1074/jbc. M410480200)
144. Takada I, Suzawa M, Matsumoto K & Kato S 2007 Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Annals of the New York Academy of Sciences 1116 182-195. (doi:10.1196/annals.1402.034)
145. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P & Karsenty G 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111 305-317. (doi:10.1016/S0092- 8674(02)01049-8)
146. Tamas P, Hawley SA, Clarke RG, Mustard KJ, Green K, Hardie DG & Cantrell DA 2006 Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2C in T lymphocytes. Journal of Experimental Medicine 203 1665-1670. (doi:10.1084/jem.20052469)
147. van Thuijl H, Kola B & Korbonits M 2008 Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase. Vitamins and Hormones 77 121-148.
148. Tomaselli S, Meli M, Plescia J, Zetta L, Altieri DC, Colombo G & Ragona L 2010 Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain. Chemical Biology & Drug Design 76 382-391. (doi:10.1111/j.1747- 0285.2010.01015.x)
149. Tsou P, Zheng B, Hsu CH, Sasaki AT & Cantley LCA 2011 A fluorescent reporter of AMPK activity and cellular energy stress. Cell Metabolism 13 476-486. (doi:10.1016/j.cmet.2011.03.006)
150. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE et al. 2008 Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57 1414-1418. (doi:10.2337/db07-1552)
151. Utting JC, Robins SP, Brandao-Burch A, Orriss IR, Behar J & Arnett TR 2006 Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Experimental Cell Research 312 1693-1702. (doi:10.1016/j.yexcr.2006.02.007)
152. van der Velde M, Delhanty P, van der Eerden B, van der Lely AJ & van Leeuwen J 2008 Ghrelin and bone. Vitamins and Hormones 77 239-258.
153. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Flamez D, Mu J,Wojtaszewski JF, Schuit FC, Birnbaum M, Richter E et al. 2003a Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochemical Society Transactions 31 216-219. (doi:10.1042/BST0310216)
154. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M et al. 2003b The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. Journal of Clinical Investigation 111 91-98.
155. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, Hue L & Andreelli F 2006 Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. Journal of Physiology 574 41-53. (doi:10.1113/jphysiol.2006.108506)
156. Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M & Andreelli F 2007 Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes & Metabolism 33 395-402. (doi:10.1016/j.diabet.2007.10.004)
157. Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R, Andreelli F & Foretz M 2009a AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiologica 196 81-98. (doi:10.1111/j.1748-1716.2009.01970.x)
158. Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz M & Andreelli F 2009b Targeting the AMPK pathway for the treatment of type 2 diabetes. Frontiers in Bioscience 14 3380-3400. (doi:10. 2741/3460)
159. Vucicevic L, Misirkic M, Janjetovic K, Vilimanovich U, Sudar E, Isenovic E, Prica M, Harhaji-Trajkovic L, Kravic-Stevovic T, Bumbasirevic V et al. 2011 Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy 7 40-50. (doi:10.4161/auto.7.1.13883)
160. WanM& Cao X 2005 BMP signaling in skeletal development. Biochemical and Biophysical Research Communications 328 651-657. (doi:10.1016/j.bbrc. 2004.11.067)
161. Wan Y, Chong LW & Evans RM 2007 PPAR-gamma regulates osteoclastogenesis in mice. Nature Medicine 13 1496-1503. (doi:10.1038/nm1672)
162. Williams GA, Wang Y, Callon KE, Watson M, Lin JM, Lam JB, Costa JL, Orpe A, Broom N, Naot D et al. 2009 In vitro and in vivo effects of adiponectin on bone. Endocrinology 150 3603-3610. (doi:10.1210/en.2008- 1639)
163. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M & Carling D 2003 LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Current Biology 13 2004-2008. (doi:10.1016/j.cub.2003.10.031)
164. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, Jing C, Walker PA, Eccleston JF, Haire LF et al. 2011 Structure of mammalian AMPK and its regulation by ADP. Nature 472 230-233. (doi:10.1038/nature09932)
165. Yamaguchi N, Kukita T, Li YJ, Kamio N, Fukumoto S, Nonaka K, Ninomiya Y, Hanazawa S & Yamashita Y 2008 Adiponectin inhibits induction of TNF-alpha/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Letters 582 451-456. (doi:10.1016/j.febslet.2007.12.037)
166. Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, Matsumoto Y, Nakamura E, Takano M, Sada KE & Makino H 2010 Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Regulatory Peptides 162 99-108. (doi:10.1016/j.regpep.2010.03.003)
167. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K et al. 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 8 1288-1295. (doi:10.1038/nm788)
168. Yang W, Hong YH, Shen XQ, Frankowski C, Camp HS & Leff T 2001 Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. Journal of Biological Chemistry 276 38341-38344. (doi:10.1074/jbc.C100316200)
169. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD & Peterson RT 2008 Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nature Chemical Biology 4 33-41. (doi:10.1038/nchembio.2007.54)
170. Zhang BB, Zhou G & Li C 2009 AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metabolism 9 407-416. (doi:10.1016/j. cmet.2009.03.012)
171. Zhao G, Iyengar RR, Judd AS, Cool B, ChiouW, Kifle L, Frevert E, Sham H & Kym PR 2007 Discovery and SAR development of thienopyridones: a class of small molecule AMPK activators. Bioorganic & Medicinal Chemistry Letters 17 3254-3257. (doi:10.1016/j.bmcl.2007.04.011)
172. Zhao J, Yue W, Zhu MJ, Sreejayan N & Du M 2010 AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552. Biochemical and Biophysical Research Communications 395 146-151. (doi:10.1016/j.bbrc. 2010.03.161)
173. Zhao JX, Yue WF, Zhu MJ & Du M 2011 AMP-activated protein kinase regulates {beta}-catenin transcription via histone deacetylase 5. Journal of Biological Chemistry 286 16426-16434. (doi:10.1074/jbc.M110. 199372)
174. Zhen D, Chen Y & Tang X 2010 Metformin reverses the deleterious effects of high glucose on osteoblast function. Journal of Diabetes and its Complications 24 334-344. (doi:10.1016/j.jdiacomp.2009.05.002)
175. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J,Wu M, Ventre J, Doebber T, Fujii N et al. 2001 Role of AMP-activated protein kinase in mechanismofmetformin action. Journal of Clinical Investigation 108 1167-1174.
176. Zhou G, Sebhat IK & Zhang BB 2009 AMPK activators - potential therapeutics for metabolic and other diseases. Acta Physiologica 196 175-190. (doi:10.1111/j.1748-1716.2009.01967.x)
177. Zong H, Ren JM, Young LH, PypaertM,Mu J, Birnbaum MJ & Shulman GI 2002 AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. PNAS 99 15983-15987. (doi:10.1073/pnas.252625599)